Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TruBridge (TBRG) Gains from Sales and Divestitures (2010 - 2012)

TruBridge's quarterly Gains from Sales and Divestitures came in at $20069.0 in Q4 2012, up 1.0% year-on-year from $19871.0 in Q1 2012, and little changed quarter-over-quarter from $20069.0 in Q3 2012.

TruBridge has reported Gains from Sales and Divestitures for 3 years, with the latest figure at $20069.0 in Q4 2012.

  • For the quarter ending Q4 2012, Gains from Sales and Divestitures rose 1.0% year-over-year to $20069.0; the trailing twelve-month figure through Dec 2012 stood at $20069.0 (up 1.0% YoY), and the FY2012 full-year result was $20069.0, up 1.0% from the prior year.
  • Gains from Sales and Divestitures for Q4 2012 stood at $20069.0, roughly flat from $20069.0 in the prior quarter.
  • The five-year high for Gains from Sales and Divestitures was $23166.0 in Q4 2010, with the low at $19871.0 in Q2 2011.
  • Average Gains from Sales and Divestitures over 3 years is $20426.6, with a median of $20069.0 recorded in 2012.
  • Year-over-year, Gains from Sales and Divestitures fell 14.22% in 2011 and increased 1.0% in 2012.
  • Tracing TBRG's Gains from Sales and Divestitures over 3 years: stood at $23166.0 in 2010, then declined by 14.22% to $19871.0 in 2011, then increased by 1.0% to $20069.0 in 2012.
  • The last three Gains from Sales and Divestitures figures came in at $20069.0 (Q4 2012), $20069.0 (Q3 2012), and $20069.0 (Q2 2012), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Veeva Systems 30.85 Bn 24.28 Bn 622.47 Mn
2 BrightSpring Health Services 12.29 Bn 11.41 Bn 482.22 Mn
3 Healthequity 7.80 Bn 7.48 Bn 256.31 Mn
4 Hinge Health 4.82 Bn 4.51 Bn 154.23 Mn
5 Doximity 4.21 Bn 3.46 Bn 125.97 Mn
6 Waystar Holding 4.18 Bn 4.03 Bn 268.04 Mn
7 10x Genomics 3.78 Bn 3.24 Bn 106.18 Mn
8 Privia Health 2.65 Bn 2.28 Bn 595.71 Mn
9 Omnicell 1.95 Bn 1.78 Bn 140.36 Mn
10 TruBridge 378.18 Mn 342.76 Mn 47.92 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2012 20,069.00
Dec 31, 2012 20,069.00
Sep 30, 2012 20,069.00
Sep 30, 2012 20,069.00
Jun 30, 2012 20,069.00
Jun 30, 2012 20,069.00
Dec 31, 2011 19,871.00
Dec 31, 2011 19,871.00
Sep 30, 2011 19,871.00
Sep 30, 2011 19,871.00
Jun 30, 2011 19,871.00
Jun 30, 2011 19,871.00
Dec 31, 2010 23,166.00
Dec 31, 2010 23,166.00